Blog - Page 615 of 5687 - QualityStocks

ThursdayOct 26, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Two New Canadian Patents Amid Continued Efforts to Safeguard the Applicability of Its DehydraTECH(TM) Technology in Multiple Jurisdictions and Sectors

Lexaria has continuously taken steps to protect its intellectual property internationally to safeguard the applicability of its patented DehydraTECH(TM) technology across the globe The company recently announced that it had received two new Canadian patents, increasing to 37 the number of granted patents in its intellectual property (“IP”) portfolio Lexaria has filed tens of patent applications in multiple jurisdictions that are considered to have the highest commercial potential The company continues to investigate opportunities that could culminate in expansions of and additions to its intellectual property portfolio and is also filing new patent applications for discoveries that arise from its…

WednesdayOct 25, 2023 3:20 pm

QualityStocksNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Schedules Q3 2023 Earnings Call

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services, has announced plans to report on its third-quarter financial results for the period ended Sept. 30, 2023. The company will issue its third quarter earnings press release before market opens on Nov. 9, 2023. In addition, D-Wave Quantum CEO Alan Baratz and CFO John Markovich will host a conference call on the same day; the call will begin at 8 a.m. ET. During the call, company officials will discuss D-Wave Quantum financial results as well as its business outlook. Those interested can access by call by dialing…

WednesdayOct 25, 2023 12:52 pm

QualityStocksNewsBreaks – Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF) Featured in Bell2Bell Podcast

Canada Nickel (TSX.V: CNC) (OTCQX: CNIKF), a company working to advance the next generation of high quality nickel sulphide projects to feed the high growth electric vehicle and stainless steel markets, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Mark Selby, CEO and director of Canada Nickel, joined the latest episode to discuss the company’s projects, including its recent news announcing the positive bankable feasibility study for its Crawford Nickel Sulphide Project. “It’s a major milestone for the company – $2.5 billion after-tax…

WednesdayOct 25, 2023 12:05 pm

QualityStocksNewsBreaks – Safety Shot (NASDAQ: SHOT) Granted Second U.S. Patent for JW-700 Treatment Designed for $1.5B Hair-Growth Market

Safety Shot (NASDAQ: SHOT), a wellness and functional beverage company, announced a “significant milestone” in its development of treatments for androgenetic alopecia, or hair loss: the granting of a second U.S. patent issued for JW-700, a topical treatment designed to improve minoxidil’s efficacy. The patent was issued by the U.S. Patent and Trademark Office. The patent adds to the growing global intellectual property (“IP”) estate for Safety Shots Legacy products. According to the announcement, minoxidil is a common treatment of hair loss sold under brand names including Rogaine(R) and Hair Regrowth for Men(R), and Safety Shot’s JW-700 has been shown to…

WednesdayOct 25, 2023 10:45 am

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters Agreements for Private Placement, Preferred Investment Options

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, has entered into a definitive agreement for the issue and sale of more than 3 million common shares, or prefunded warrants in lieu thereof. Specifically, the company agreed to a private placement of 3,012,049 common shares priced at $0.83 per share. In addition, the company entered an agreement for an associated preferred investment option as well as a definitive agreement regarding specific outstanding preferred investment options issued in November 2022. The announcement outlines specifics of the agreement. The company also…

WednesdayOct 25, 2023 9:45 am

DGE 3rd Investigator Initiated Trials Summit 2023: Unlocking Innovations in Pharma Research and Collaboration

The 3rd Investigator Initiated Trials Summit will be held on November 13-14, 2023 in Philadelphia. The DGE event is focused on exploring the most lucrative ways for reviewing, selecting, and funding research investigators. Researchers, medical officers, health and pharma executives and companies can harness the reach and network of the DGE platform to connect with industry stalwarts and discuss vital issues on how they effectively manage IITs. The speakers will offer important insights on ways to leverage the new methods for new indications, label expansion and potential publications. The conference aims to create a bridge between pharma suppliers and sponsors…

WednesdayOct 25, 2023 9:00 am

Clene Inc. (NASDAQ: CLNN) Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS

Clene's wholly-owned subsidiary, Clene Nanomedicine Inc., in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”) The study will monitor safety, survival, clinical worsening, and key disease progression-related biomarkers while using CNM-Au8 Research conducted by Clene estimates that ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the US and an estimated 500,000 people worldwide, with a life expectancy of diagnosed patients typically ranging from three to five years Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company on…

TuesdayOct 24, 2023 12:20 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Advance INM-901 Following Positive Proof-of-Concept Results

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced its selection of a lead Alzheimer’s disease drug candidate, named INM-901, following positive results from several proof-of-concept studies in a validated Alzheimer’s treatment model. InMed will be advancing cannabinoid analog INM-901 in its pharmaceutical drug development program. “The most recent studies of INM-901 demonstrate promising disease-modifying effects in an Alzheimer’s disease treatment model,” said Dr. Eric Hsu, InMed’s SVP of preclinical research and development. “We are optimistic that the next stage of studies will continue to show how…

TuesdayOct 24, 2023 12:09 pm

QualityStocksNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Top-Line Results from Phase 2a Trial Spotlighted in Latest NNA Release

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, is featured in a recent NetworkNewsAudio (“NNA”) broadcast. The segment focuses on the company’s most recent announcement of its topline results from the CLEAR Mind phase 2a clinical trial of LGVN’s Lomecel-B(TM) for the treatment of mild Alzheimer's disease. According to the segment, the Lomecel-B study met its primary safety endpoint and is supported by lack of deterioration in cognitive or atrophy signals. The encouraging results will be used as a foundation…

TuesdayOct 24, 2023 11:41 am

QualityStocksNewsBreaks – GEMXX Corporation (GEMZ) Releases Gold Production Report for BC-Based Snow Creek Test Mine Site

GEMXX (OTC: GEMZ), a leader in the ammolite gemstone mine-to-market segment and a 50% partner in Canadian gold-exploration company Crazy Horse Mining Inc. (“CHMI”), has successfully completed its third and final clean-out and recording of gold production at the Snow Creek Mine site for the 2023 mining season. According to the announcement, GEMXX and CHMI have processed 31,200 cubic yards of gold-bearing ore during the 2023 test season; those results met all expectations, the report noted, and are positive considering much of the material used during the test program was surface “gold bearing ore” that had been stockpiled when making…

Site Search

Company Search